Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period.
Hyuk HuhYong Soo KimWookyung ChungYong Lim KimYaerim KimSeungyeup HanYeon Soon JungKi Young NaKyu Beck LeeYun Kyu OhHyeong Cheon ParkSeung Hyeok HanTae Hyun YooYeong Hoon KimSoo Wan KimKang Wook LeeHayne Cho ParkSung Gyun KimHyunsuk KimChang Hwa LeeKyongtae T BaeKook Hwan OhCurie AhnHyun Jin RyuYong Chul KimPublished in: Kidney research and clinical practice (2023)
We observed short-term effects and safety during the tolvaptan titration period, with the greatest decrease in kidney function occurring during the first week. The decline of htTKV can be predicted as a short-term effect of tolvaptan by observing Uosm changes from baseline to end of titration in 1D and baseline eGFR in 1E groups.